Dr Brian Maas is an associate principal scientist in the quantitative pharmacology and pharmacometrics group at Merck Sharp & Dohme. Brian graduated from the University of Florida in 2015 with his Doctor of Pharmacy. He went on to complete a clinical pharmacology and pharmacometrics fellowship at the University of North Carolina, with a focus on tissue distribution of antiretrovirals and pharmacokinetics of monoclonal antibodies. Since joining Merck Sharp and Dohme in 2017, Brian has served as the clinical pharmacology lead for several candidate compounds for RSV, HIV, and COVID-19. He is interested in applying mathematical models across different modalities to streamline development and bring drugs to patients in need.

Denis Macina is an epidemiologist with 20+ years experience working in the vaccines industry. His research work focuses primarily on pertussis, ranging from disease burden characterization to evaluation of vaccine interventions. He has collaborated on more than 50 studies worldwide, contributing to build the body of evidence that supports the need and benefit of pertussis vaccination from infancy to old-age, with a special interest for vaccination in pregnancy.

NA